Compliance Certificate - Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Half Year Ended 30Th September, 2017
Compliance Certificate - Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Compliance Certificate - Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Half Year Ended 30Th September, 2017
Compliance Certificate - Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Shareholding for the Period Ended September 30, 2017
Piramal Enterprises Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here Statement Of Investor Complaints Under Regulation 13(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Quarter Ended 30Th September, 2017
Statement of Investor Complaints for quarter ended 30th September, 2017 
Piramal Enterprises to raise Rs5,000 crore through QIP
Piramal Enterprises intends to use funds for both organic and inorganic growth opportunities in the financial services business Piramal Enterprises: focus on fund raising
Shares of Piramal Enterprises will remain in focus, as the company board is meeting on Thursday to consider various fund raising options. The board will also consider a scheme of amalgamation of... Piramal invests $55 million to upgrade API plants
In a boost to its contract manufacturing business, Piramal Enterprises has invested $ 55 million (around Rs 360 crore ) to upgrade its active pharmaceutical ingredient manufacturing plants in India and the US.Healthcare is the largest segment of the company and contributed to around 47 per cent of the company's FY 17 revenue of Rs 8547 crore. Within healthcare, contract manufacturing is the largest division accounting for 60 per cent of the segment revenue in last fiscal.The contract manufacturing business supports clinical trials and drug development of other companies. It has five manufacturing sites in India, the US and Europe.A part of the investment will go into a new state of art multi purpose plants to support the current pipeline of around 80 late stage programmes that the company is currently assisting its partners. The investment has been made through group company Piramal Pharma Solutions.Upgrades will include creation of early development capabilities, addition of GMP... Board Meeting On 12Th October, 2017
Raising of Funds and Scheme of Amalgamation of wholly owned subsidiaries Piramal Finance sanctions Rs 280 cr to Puranik Builders
Piramal Enterprises Ltd, through its subsidiary Piramal Finance Limited (PFL), has sanctioned Rs 280 crore to Puranik Builders for one of its flagship projects in Thane. Piramal Finance, through...